Year: 2022
Type: review
Study design: Systematic Review
Abstract: In this systematic review, we foresee what could be the approved scenario in the next few years for CAR-T cell therapies directed against hematological and solid tumor malignancies. China and the USA are the leading regions in numbers of clinical studies involving CAR-T. Hematological antigens CD19 and BCMA are the most targeted, followed by mesothelin, GPC3, CEA, MUC1, HER2, and EGFR for solid tumors. Most CAR constructs are second-generation, although third and fourth generations are being largely explored. Moreover, the benefit of combining CAR-T treatment with immune checkpoint inhibitors and other drugs is also being assessed. Data regarding product formulation and administration, such as cell phenotype, transfection technique, and cell dosage, are scarce and could not be retrieved. Better tracking of trials' status and results on the ClinicalTrials.gov database should aid in a more concise and general view of the ongoing clinical trials involving CAR-T cell therapy.
Source: Cancers
Authors: Luciana Rodrigues Carvalho Barros(Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft), Samuel Campanelli Freitas Couto(Conceptualization, Data curation, Methodology, Writing – original draft, Writing – review & editing), Daniela da Silva Santurio(Data curation), Emanuelle Arantes Paixão(Data curation), Fernanda Cardoso(Data curation), Viviane Jennifer da Silva(Data curation), Paulo Klinger(Data curation), Paula do Amaral Costa Ribeiro(Data curation), Felipe Augusto Rós(Data curation), Théo Gremen Mimary Oliveira(Data curation), Eduardo Magalhães Rego(Writing – review & editing), Rodrigo Nalio Ramos(Conceptualization, Writing – original draft, Writing – review & editing), Vanderson Rocha(Funding acquisition, Methodology, Supervision, Writing – review & editing)
Institutions: Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Fundação Pró-Sangue Hemocentro de São Paulo, Laboratório Nacional de Computação Científica, Universidade de São Paulo, D’Or Institute for Research and Education, Churchill Hospital, University of Oxford
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,513
OpenAlex ID: W4281965930
